Summary of the 2023 international evidence‐based guideline for the assessment and management of polycystic ovary syndrome: an Australian perspective

Author:

Teede Helena J1,Mousa Aya1,Tay Chau T1,Costello Michael F234,Brennan Leah5,Norman Robert J6,Pena Alexia S6,Boyle Jacqueline A7,Joham Anju1,Berry Lorna8,Moran Lisa16

Affiliation:

1. Monash Centre for Health Research and Implementation Monash University Melbourne VIC

2. University of New South Wales Sydney NSW

3. Royal Hospital for Women Sydney NSW

4. Monash IVF Sydney NSW

5. La Trobe University Melbourne VIC

6. Robinson Research Institute University of Adelaide Adelaide SA

7. Monash University Melbourne VIC

8. Polycystic Ovary Syndrome Association of Australia Sydney NSW

Abstract

AbstractIntroductionThe Australian‐led 2023 International evidence‐based guideline for the assessment and management of polycystic ovary syndrome was based on best available evidence, clinical expertise and consumer preference. It followed best practice, involved extensive evidence synthesis and applied relevant frameworks across evidence quality, feasibility, acceptability, cost and implementation. Thirty‐nine societies and organisations covering 71 countries were engaged. The evidence in the assessment and management of polycystic ovary syndrome (PCOS) has generally improved in the past five years, but remains of low to moderate quality. The technical evidence report, 52 systematic reviews and analyses (approximately 6000 pages) underpin 77 evidence‐based and 54 consensus recommendations, with 123 practice points.Main recommendationsChanges include: refinement of individual diagnostic criteria, a simplified diagnostic algorithm and inclusion of anti‐Müllerian hormone levels as an alternative to ultrasound in adults only, and differentiation of adolescent and adult criteria; strengthening the recognition of broad features of PCOS including metabolic effects, cardiovascular disease, dermatological symptoms, sleep apnoea, a high prevalence of psychological features and a high risk of adverse pregnancy outcomes; emphasising the poorly recognised, diverse burden of disease, the vital need for greater health professional education, evidence‐based patient information, improved models of care, shared decision making and research efforts to improve patient experience; maintained emphasis on healthy lifestyle, emotional wellbeing and quality of life, with awareness and consideration of weight stigma; and emphasising evidence‐based medical therapy and cheaper and safer fertility management. Changes in management as a result of this guidelineThe 2023 guideline is approved by the National Health and Medical Research Council and provides clinicians and patients with clear advice on best practice in a common and neglected condition, based on the best available evidence, expert multidisciplinary input and consumer preferences. It provides vital, extensive patient and provider resources to enhance evidence‐based care.The full guideline is available at www.monash.edu/medicine/mchri/pcos/guideline.

Funder

National Health and Medical Research Council

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3